Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis

Wang, Hu; Wang, Li; Cheng, Yun; Xia, Zhiqing; Liao, Yifeng; Cao, Jiang

doi:10.3892/br.2018.1100

Cited by 36 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, oral administration of asperlin for 12 weeks significantly prevented bodyweight gain, decreased fat deposit, and reduced body fat rate and Lee’s index. These effects were similar to those elicited by the approved anti-obesity drug, orlistat [23], as well as natural products such as cordycepin [24] and berberine [25], demonstrating potent activity against HFD-induced obesity. Simultaneously, asperlin noticably ameliorated hyperlipidemia and liver steatosis.…”

Section: Discussionmentioning

confidence: 52%

Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice

Zhou

et al. 2019

Marine Drugs

View full text Add to dashboard Cite

Asperlin is a marine-derived, natural product with antifungal, anti-inflammatory and anti-atherosclerotic activities. In the present study, we showed that asperlin effectively prevented the development of obesity in high-fat diet (HFD)-fed mice. Oral administration of asperlin for 12 weeks significantly suppressed HFD-induced body weight gain and fat deposition without inhibiting food intake. Hyperlipidemia and liver steatosis were also substantially ameliorated. A respiratory metabolism monitor showed that asperlin efficiently increased energy expenditure and enhanced thermogenic gene expression in adipose tissue. Accordingly, asperlin-treated mice showed higher body temperature and were more tolerant of cold stress. Meanwhile, asperlin also increased the diversity and shifted the structure of gut microbiota. Oral administration of asperlin markedly increased the relative abundance of Bacteroidetes, leading to a higher Bacteroidetes-to-Fimicutes ratio. The HFD-induced abnormalities at both phylum and genus levels were all remarkably recovered by asperlin. These results demonstrated that asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota. Its anti-obesity properties may be attributed to its effect on promoting energy expenditure.

show abstract

Section: Discussionmentioning

confidence: 52%

Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice

Zhou

et al. 2019

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…They suggested that orlistat could serve as a therapeutic drug in improving biochemical indicators of liver damage, suggesting a novel palliative drug for the treatment of NAFLD. 20…”

Section: Discussionmentioning

confidence: 99%

Efficacy of orlistat in the treatment of patients with non-alcoholic fatty liver

Alamdari

Habibzadeh

Ahad

et al. 2020

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Nonalcoholic fatty liver disease (NAFLD) is a reversible condition of fat accumulation that is associated with liver inflammation and can disrupt the normal activity of the liver. People with a diagnosis of NAFLD have a higher risk of all- cause mortality than the general population. The purpose of the present study was to determine, the efficacy of orlistat in the treatment of patients with NAFLD.Methods: This semi-experimental study was performed on 45 fatty liver patients of the gastroenterology clinic of Imam Khomeini Hospital in Ardabil city in April 2016 to April 2017. Data was collected by a checklist which included demographic and clinical data such as age, sex, body mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol and result of ultrasound before and after orlistat consumption.Results: The mean decrease in the variables examined was as follows: weight 8.3 kg, BMI 3.5 kg/m2, ALT 31.6 U/l, AST 18.1 U/l, cholesterol 15.5 mg/dl and TG 33.1 mg/dl. All of the upper indexes were decreased significantly following received drug.Conclusions: Orlistat therapy was associated with significant decreases in ALT, AST, TG and cholesterol level. Orlistat is effective in weight loss, body mass index reduction and can be used to treat non-alcoholic fatty liver disease.

show abstract

“…However, subjects who lost ≥5% of body weight over 9 months showed improved insulin resistance and steatosis, and those subjects who lost ≥9% also achieved improvement in liver histology and NAS [105]. In a meta-analysis, orlistat improved liver enzymes but not liver fibrosis score ( P =0.71) in patients with NAFLD [106].…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

et al. 2019

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

show abstract

Efficacy of orlistat in non‑alcoholic fatty liver disease: A systematic review and meta‑analysis

Cited by 36 publications

References 31 publications

Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice

Asperlin Stimulates Energy Expenditure and Modulates Gut Microbiota in HFD-Fed Mice

Efficacy of orlistat in the treatment of patients with non-alcoholic fatty liver

Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

Contact Info

Product

Resources

About